HUE036524T2 - Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept - Google Patents

Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept

Info

Publication number
HUE036524T2
HUE036524T2 HUE13838016A HUE13838016A HUE036524T2 HU E036524 T2 HUE036524 T2 HU E036524T2 HU E13838016 A HUE13838016 A HU E13838016A HU E13838016 A HUE13838016 A HU E13838016A HU E036524 T2 HUE036524 T2 HU E036524T2
Authority
HU
Hungary
Prior art keywords
yielded
highly purified
correctly folded
folded etanercept
etanercept
Prior art date
Application number
HUE13838016A
Other languages
English (en)
Hungarian (hu)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036524(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of HUE036524T2 publication Critical patent/HUE036524T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13838016A 2012-09-11 2013-09-10 Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept HUE036524T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
HUE036524T2 true HUE036524T2 (hu) 2018-07-30

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13838016A HUE036524T2 (hu) 2012-09-11 2013-09-10 Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept

Country Status (33)

Country Link
US (6) US20140072560A1 (enExample)
EP (1) EP2895188B1 (enExample)
JP (3) JP2015533797A (enExample)
KR (2) KR102133699B1 (enExample)
CN (2) CN104902914B (enExample)
AR (1) AR092532A1 (enExample)
AU (2) AU2013315750B9 (enExample)
BR (1) BR112015005161A2 (enExample)
CA (1) CA2882551A1 (enExample)
CL (1) CL2015000572A1 (enExample)
CO (1) CO7400876A2 (enExample)
CY (1) CY1120062T1 (enExample)
DK (1) DK2895188T3 (enExample)
DO (1) DOP2015000055A (enExample)
EA (1) EA031324B1 (enExample)
EC (1) ECSP15014138A (enExample)
ES (1) ES2657377T3 (enExample)
HR (1) HRP20180182T1 (enExample)
HU (1) HUE036524T2 (enExample)
IL (2) IL237311B (enExample)
IN (1) IN2015KN00452A (enExample)
LT (1) LT2895188T (enExample)
MX (2) MX360044B (enExample)
NO (1) NO2972131T3 (enExample)
PE (2) PE20150996A1 (enExample)
PL (1) PL2895188T3 (enExample)
PT (1) PT2895188T (enExample)
RS (1) RS57013B1 (enExample)
SG (1) SG11201501460RA (enExample)
SI (1) SI2895188T1 (enExample)
SM (1) SMT201800163T1 (enExample)
TW (2) TWI716649B (enExample)
WO (1) WO2014043103A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010654B (zh) 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HRP20180182T1 (hr) * 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
US10556942B2 (en) 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
MX394035B (es) * 2014-12-31 2025-03-21 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
AU2016356482A1 (en) * 2015-11-18 2018-06-28 Merck Patent Gmbh Opposite pH-salt gradients for improved protein separations
BR112018009881A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh separação de proteína aperfeiçoada em cromatografia de troca iônica
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
JP6884858B2 (ja) * 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EP3601332A1 (en) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research A process for the purification of recombinant antibody fragments
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
PL374045A1 (en) 2001-02-23 2005-09-19 Immunex Corporation Efficient recovery of correctly refolded proteins
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
DE60236025D1 (de) * 2002-08-22 2010-05-27 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l-arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
PL213501B1 (pl) 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
JP2007521315A (ja) 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
NZ548126A (en) * 2004-02-27 2009-10-30 Ge Healthcare Bio Sciences Ab A process for the purification of antibodies involving addition of a second resin
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
ES2748526T3 (es) 2006-12-21 2020-03-17 Amgen Inc Formulaciones tamponadas estables que contienen polipéptidos
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
JP2010529999A (ja) 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
AU2009222115A1 (en) * 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
KR101415660B1 (ko) 2009-08-07 2014-07-16 이엠디 밀리포어 코포레이션 샘플 중의 1 이상의 불순물로부터 표적 단백질을 정제하는 방법
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
WO2011049798A1 (en) * 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
BR112012027282B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Meio de cultura de células aperfeiçoado e processo para a produção de um polipeptídeo recombinante
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
SG187885A1 (en) 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
SG10201508401TA (en) * 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
ES2759931T3 (es) 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
MX358137B (es) 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
WO2013025079A1 (en) * 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010654B (zh) * 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
HRP20180182T1 (hr) * 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
WO2016015163A1 (en) * 2014-07-31 2016-02-04 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
IL237311B (en) 2019-07-31
SG11201501460RA (en) 2015-04-29
HRP20180182T1 (hr) 2018-04-20
EP2895188A4 (en) 2016-05-25
US11001627B2 (en) 2021-05-11
DK2895188T3 (en) 2018-02-26
ES2657377T3 (es) 2018-03-05
BR112015005161A2 (pt) 2017-07-04
TW201425331A (zh) 2014-07-01
AR092532A1 (es) 2015-04-22
IL267452A (en) 2019-08-29
ECSP15014138A (es) 2016-01-29
TWI609877B (zh) 2018-01-01
EP2895188A1 (en) 2015-07-22
PE20200607A1 (es) 2020-03-10
US10947306B2 (en) 2021-03-16
AU2013315750A1 (en) 2015-03-05
CL2015000572A1 (es) 2016-02-05
MX2018012749A (es) 2020-11-12
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (enExample) 2018-04-21
EP2895188B1 (en) 2017-11-15
TWI716649B (zh) 2021-01-21
IL267452B (en) 2021-05-31
US10954293B2 (en) 2021-03-23
CA2882551A1 (en) 2014-03-20
US20190300600A1 (en) 2019-10-03
US20180037642A1 (en) 2018-02-08
LT2895188T (lt) 2018-04-10
DOP2015000055A (es) 2015-04-30
PE20150996A1 (es) 2015-08-01
WO2014043103A1 (en) 2014-03-20
MX2015003090A (es) 2015-07-14
CN104902914B (zh) 2019-01-01
AU2013315750B2 (en) 2018-07-12
IL237311A0 (en) 2015-04-30
US10954295B2 (en) 2021-03-23
JP2015533797A (ja) 2015-11-26
PT2895188T (pt) 2018-02-08
JP6913066B2 (ja) 2021-08-04
CO7400876A2 (es) 2015-09-30
AU2013315750B9 (en) 2018-11-15
US20190300602A1 (en) 2019-10-03
CY1120062T1 (el) 2018-12-12
CN110051823A (zh) 2019-07-26
US20190300601A1 (en) 2019-10-03
MX360044B (es) 2018-10-19
EA201590542A1 (ru) 2015-07-30
US20190330325A1 (en) 2019-10-31
CN104902914A (zh) 2015-09-09
AU2018247244B2 (en) 2020-05-28
KR102133699B1 (ko) 2020-07-14
JP2021100929A (ja) 2021-07-08
RS57013B1 (sr) 2018-05-31
KR20150056601A (ko) 2015-05-26
PL2895188T3 (pl) 2018-06-29
SI2895188T1 (en) 2018-05-31
EA031324B1 (ru) 2018-12-28
US10954294B2 (en) 2021-03-23
SMT201800163T1 (it) 2018-05-02
IN2015KN00452A (enExample) 2015-07-17
JP2019038817A (ja) 2019-03-14
AU2018247244A1 (en) 2018-11-01
KR20200085937A (ko) 2020-07-15
US20140072560A1 (en) 2014-03-13
TW201803593A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
HUE036524T2 (hu) Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
EP2921183A4 (en) AIR CLEANER
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
EP2802603A4 (en) REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
EP2706964A4 (en) NASAL DILATOR
EP2632531A4 (en) NASAL DILATOR
IL229963A0 (en) Substituted quinolines and their use as medicaments
HRP20181874T1 (hr) Anti-cxcr3 protutijela
EP2937066A4 (en) FACE PLASTER
EP2818054A4 (en) METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
DK2745744T3 (da) Tilbagefoldet pocketmadras
EP2844571A4 (en) Faltflasche
EP2823035A4 (en) ADHÄSIONSSIGNATUREN
HUE053623T2 (hu) Vegyületek és azok felhasználása
EP2909160A4 (en) HALOGENATION OF HYDROCARBONS
EP2802983A4 (en) ISA BRIDGE WITH RECALL
EP3050877A4 (en) Cyclic amine derivative and pharmaceutical use thereof
FR3000244B1 (fr) Module d'interface
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen
FR3000245B1 (fr) Module d'interface
ES1075514Y (es) Salabre plegable y extensible
FR3000243B1 (fr) Module d'interface
FI9997U1 (fi) Marjojen puhdistuslaite